Sigilon Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview

Sigilon Therapeutics

04/11/2022 17:02

* Sigilon Therapeutics Inc  SGTX.OQ   SGTX.O  is expected
to show
a rise in quarterly revenue when it reports  results on November
8 (estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 28.4% increase in revenue to $2.5 million from $1.95 million
a year ago, according to the mean estimate from 2 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Sigilon
Therapeutics Inc
is for a loss of 42 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Sigilon
Therapeutics Inc is $3​, above​ its last closing price of $0.56.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.44       -0.43      -0.44     Missed  -1.7
 Mar. 31 2022  -0.33       -0.33      -0.43     Missed  -29.3
 Dec. 31 2021  -0.56       -0.56      -0.55     Beat    2.1​
 Sep. 30 2021  -0.70       -0.66      -0.63     Beat    4.3
 ​​Jun.        -0.57       -0.63      -0.65     Missed  -3.6
 30 2021                                                
 Mar. 31 2021  -0.61       -0.59      -0.60     Missed  -1.1​
 Dec. 31 2020  -1.37       -1.37      -1.15     Beat    16.1
 This summary was machine generated November 4 at 17:02 GMT.  All
figures in US dollars  unless otherwise stated